Professor Beth Stadtmueller and Sonya Kumar Bharathkar have created a chimeric secretory immunoglobulin A (cSIgA) with a modified secretory component (SC) that can be used in therapeutic treatment. The bispecific cSIgA can bind its target antigen and additional ligands by an engineered SC portion, such as toxins or surface antigens. This can be applied to treatment for mucosal infections such as Clostridium difficile.